Digital pathology is used within pathology, computer science and image analysis and is transforming how pathologists diagnose and research diseases. Within this article, we will conduct a deep dive into the benefits of digital pathology. While doing this, we will emphasise its impact on healthcare outcomes, research and education.
Read article here:
https://sourcebioscience.com/what-are-the-benefits-of-digital-pathology/
Stevenage, UK, 22 October 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October.
Led by COO Tom Payne, Laverock’s team of scientists will be presenting three posters covering the Company’s technology platform and its application to CAR T cells and tumour microenvironment (TME) responsive macrophages for…
CPI has fully opened its RNA Centre of Excellence to support the rising demand for RNA-based therapies and vaccines. The service offers comprehensive support, including plasmid DNA production, RNA transcription, purification, and formulation, alongside process development, analytics, and regulatory guidance.
Located at CPI’s National Biologics Manufacturing Centre in Darlington, the RNA Centre helps companies at all stages, from research to clinical trials, scale up RNA production. The GMP facility has been set up to enable industry to take projects from DNA to…
tranScrip is delighted to announce the appointment of Roz Sutton as Senior Director of Regulatory Affairs. Roz brings two decades of experience in Global Regulatory Affairs, having held leadership roles at top pharmaceutical companies including Roche and GSK, as well as in regulatory consultancy at DLRC. Her appointment underscores tranScrip’s commitment to strengthening its regulatory team as it continues to expand its expertise and service offerings.
A highly experienced regulatory strategist, Roz has led regulatory initiatives across key therapeutic areas such as ophthalmology,…
We are delighted to announce that Dr. Kathryn (Kate) Owen has joined tranScrip as Executive Medical Director in our Early Development Group.
Kate brings with her 24 years of extensive experience as a consultant Pharmaceutical Physician, with a specialised focus in oncology and haemato-oncology. She has an exceptional track record in early clinical development, guiding projects from candidate drug selection through to phase IIb trials.
Throughout her 16-year career at AstraZeneca, Kate held various pivotal roles in early development, before transitioning into consultancy. For the past 8 years…
Government’s ambitions to solve NHS crisis lack sufficient detail.
Collaboration with private sector and life sciences is crucial to tackle NHS backlog and provide much needed investment.
Tax and fiscal incentives important to encourage investment in the sector.
Regulation and procurement barriers must be tackled if innovative solutions are to feed through to the NHS.
15 October 2024
The UK government has made a commitment to solving the NHS crisis but is yet to provide any detail on how this will work in practice. Pressure is now building on the Chancellor to provide much needed…
Cambridge, UK – 16 October 2024 – The Cambridge Crystallographic Data Centre (CCDC) announces two significant scientific papers detailing the findings of the 7th Crystal Structure Prediction (CSP) Blind Test. To coincide with the publication of the two papers, the CCDC has released a CSP Blind Test database that contains 171,679 entries from 207 landscapes.
Expanding CSP Beyond Pharmaceuticals
CSP predicts the most likely crystal structures to form from a given molecule, based on its 2D chemical structure. Most methods use informatics and computational science techniques. Predicting more…
Glucose sensing and continuous glucose monitoring (CGM) manufacturer for diabetes management, Dexcom, and pharmaceutical and medical devices organisation, Abbott, have been locked in a series of patent disputes over their continuous glucose monitoring (CGM) devices and systems, in a battle that spans multiple patents and several jurisdictions including the UK, US and Germany. In the UK alone, both parties have brough infringement proceedings, with a total of seventeen patents being at issue.
A recent decision issued by the Unified Patent Court (UPC) sees one of Dexcom’s patents revoked in its…
In January 2024 Cameroon launched the world’s first routine malaria vaccine programme. By incorporating the RTS,S vaccine into its standard immunisation schedule, Cameroon aims to protect thousands of children across Africa and significantly reduce malaria-related fatalities.
Closely following suit, the Côte d’Ivoire has recently become the first country to roll-out the new R21/Matrix-M™ vaccine, in another key advancement in the battle against malaria.
The launch of the vaccines, and the implementation of the mass vaccination programmes, marks a historic step in the global fight against…
Series C round led by Elevage Medical Technologies
Funding will accelerate the commercialization of Nuclera’s eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally
Cambridge, UK, and Boston MA, USA, 16 October 2024: Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, today announced it has completed a USD $75 million financing round (circa £57 million). The fundraise was led by Elevage Medical Technologies, backed by Patient Square Capital, and joined…